Stockreport

Calithera Biosciences to Present Telaglenastat KEAPSAKE Trial in Progress Poster at ASCO20 Virtual Annual Meeting

Calithera Biosciences, Inc.  (CALA) 
Last calithera biosciences, inc. earnings: 3/11 04:10 pm Check Earnings Report
US:NASDAQ Investor Relations: calithera.com
PDF KEAPSAKE is a planned Phase 2 randomized trial exploring telaglenastat with standard of care in first-line treatment of patients with lung cancer with KEAP1/NRF2 mutatio [Read more]